Literature DB >> 8914556

The female condom (Femidom)--a study of user acceptability.

K E Sapire1.   

Abstract

OBJECTIVE: To determine the acceptability of the female condom (Femidom).
DESIGN: Questionnaire survey following the use of the Femidom during sexual intercourse.
SETTING: Groote Schuur and Somerset Hospitals, Cape Town. PARTICIPANTS: Nurses, secretaries, doctors and domestic staff of Groote Schuur and Somerset Hospitals who volunteered-61 women were recruited, 8 did not use any female condoms, and 1 did not return. Many women refused, mainly because of the unaesthetic appearance of the Femidom and the fact that they had to continue using their regular contraceptive and they did not think their partners would co-operate. OUTCOME MEASURES: Sexual responsivity compared with that without Femidom; acceptability of the method; women's and their partners' enjoyment of using the method; comparison with the male condom; awareness of HIV-AIDS and protective measures that can be used.
RESULTS: Of the 52 participants, 23 used all 10 Femidoms issued to them. Thirteen women and 18 of their partners did not enjoy using the method and 9 had problems with it. Sex with the Femidom was the same or better in 51.9%. The Femidom was unacceptable in 32.7%, acceptable in 52% and very acceptable in 13.4%. Compared with the male condom, 50% of women and 44.2% of men considered the Femidom as good or better. Of the 61 women, 59 had heard of AIDS, and awareness of protective measures was good.
CONCLUSION: There was resistance to accepting the Femidom, mainly because of its unaesthetic appearance and because women were participating for altruistic reasons. Acceptance and ease of application improved with use. Comments regarding problems and subjects' and their partners' enjoyment varied from extremely positive to extremely negative; 65.4% considered sex using the Femidom acceptable or very acceptable. It is important to inform and obtain co-operation from the male partner. The female condom has been developed as an alternative for women to use if their partners refuse or dislike using male condoms. Perfect use of the Femidom may reduce the annual risk of acquiring HIV by more than 90% in women who are sexually active with an infected male. The efficacy of the female condom has been described as equal to that of the diaphragm. The Femidom will increase the range of choices of contraceptives and prophylactic methods available for protective sex. It should become accepted as a method of contraception and an adjunct to other contraceptive methods as a prophylactic against sexually transmitted diseases and AIDS, particularly in relationships that are not mutually monogamous.

Entities:  

Mesh:

Year:  1995        PMID: 8914556

Source DB:  PubMed          Journal:  S Afr Med J


  5 in total

1.  Effect of an STD/HIV behavioral intervention on women's use of the female condom.

Authors:  Nancy Van Devanter; Virginia Gonzales; Cheryl Merzel; Nina S Parikh; David Celantano; Judith Greenberg
Journal:  Am J Public Health       Date:  2002-01       Impact factor: 9.308

2.  Building young women's knowledge and skills in female condom use: lessons learned from a South African intervention.

Authors:  A C Schuyler; T B Masvawure; J A Smit; M Beksinska; Z Mabude; C Ngoloyi; J E Mantell
Journal:  Health Educ Res       Date:  2016-03-08

3.  High-risk women's willingness to try a simulated vaginal microbicide: results from a pilot study.

Authors:  Katie E Mosack; Margaret R Weeks; Laurie Novick Sylla; Maryann Abbott
Journal:  Women Health       Date:  2005

4.  Willingness to use microbicides varies by race/ethnicity, experience with prevention products, and partner type.

Authors:  Kathleen M Morrow; Joseph L Fava; Rochelle K Rosen; Anna L Christensen; Sara Vargas; Candelaria Barroso
Journal:  Health Psychol       Date:  2007-11       Impact factor: 4.267

Review 5.  Barriers and Facilitators to Acceptability of the Female Condom in Low- and Middle-Income Countries: A Systematic Review.

Authors:  Luther-King Fasehun; Sarah Lewinger; Oyinlola Fasehun; Mohamad Brooks
Journal:  Ann Glob Health       Date:  2022-03-10       Impact factor: 2.462

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.